Chemotherapy for Neuroendocrine Cancer
Trial Summary
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot be on any investigational agents or Coumadin while participating. Other anticoagulants are allowed.
What data supports the effectiveness of the drug combination of capecitabine and temozolomide for neuroendocrine cancer?
Research shows that the combination of capecitabine and temozolomide is promising for treating well-differentiated neuroendocrine tumors, with manageable side effects and improved outcomes. In patients with metastatic pancreatic endocrine carcinomas, this combination has shown synergistic effects, enhancing the treatment's effectiveness.12345
Is chemotherapy with temozolomide and capecitabine safe for treating neuroendocrine cancer?
What makes the chemotherapy treatment for neuroendocrine cancer unique?
This treatment is unique because it combines capecitabine and temozolomide, which are taken orally, offering a more convenient option compared to traditional intravenous chemotherapy. This combination has shown promising results with manageable side effects, especially for well-differentiated neuroendocrine tumors, which are typically resistant to other chemotherapy options.12478
What is the purpose of this trial?
This trial is testing two different sets of cancer drugs to see which works better for patients with advanced neuroendocrine carcinoma that has spread or cannot be removed by surgery. The drugs aim to stop cancer from growing and spreading by attacking the cancer cells in different ways. One of the drugs being tested is used for treating advanced neuroendocrine tumors.
Research Team
Jennifer Eads
Principal Investigator
ECOG-ACRIN Cancer Research Group
Eligibility Criteria
This trial is for adults with advanced, inoperable or metastatic neuroendocrine carcinoma of the gastrointestinal tract or pancreas. They should not have had prior systemic treatment for this cancer and must be physically well enough to participate (ECOG 0-2). Participants need functioning major organs, no severe allergies to study drugs, no other cancers unless specific conditions are met, and cannot be pregnant. Effective contraception is advised.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either capecitabine and temozolomide or cisplatin/carboplatin and etoposide based on randomization
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Capecitabine
- Carboplatin
- Cisplatin
- Etoposide
- Temozolomide
Capecitabine is already approved in European Union, United States, Canada, Japan for the following indications:
- Colorectal cancer
- Breast cancer
- Colorectal cancer
- Breast cancer
- Colorectal cancer
- Breast cancer
- Colorectal cancer
- Breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
ECOG-ACRIN Cancer Research Group
Lead Sponsor
National Cancer Institute (NCI)
Collaborator